Circulating Tumor Cells in the Management of Breast Cancer

Nagaiah, Govardhanan; Abraham, Jame

doi:10.3816/cbc.2010.n.028

Cited by 17 publications

(15 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The luciferase activity of the extracts was determined 24 h after transfection using a Betascope analyzer. Luciferase values are normalized with Renilla activities mortality in breast cancer patients (Jemal et al 2009;Nagaiah and Abraham 2010). Because of this clinical importance, detection and treatment of breast cancer metastasis have been urgently researched.…”

Section: Discussionmentioning

confidence: 99%

BMP-6 inhibits MMP-9 expression by regulating heme oxygenase-1 in MCF-7 breast cancer cells

Guo

et al. 2010

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

BMP-6 inhibits MMP-9 expression by regulating heme oxygenase-1 in MCF-7 breast cancer cells

Guo

et al. 2010

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…In addition, identification of DTCs could help in decision making on the need of therapy and to predict the outcome of treatment (5). Alternatively to bone marrow samples, which are difficult to obtain in a routine fashion, blood has been shown to be a valuable source for the identification of dissociated tumor cells (6)(7)(8). Detection of these circulating tumor cells (CTC) might be used to monitor and predict therapy response in cancer treatment because repeated samples can be taken easily (9)(10)(11).…”

Section: Introductionmentioning

confidence: 99%

Changes in Keratin Expression during Metastatic Progression of Breast Cancer: Impact on the Detection of Circulating Tumor Cells

Joosse

Hannemann

Spötter

et al. 2012

Clinical Cancer Research

129

113

View full text Add to dashboard Cite

Purpose: Circulating tumor cells (CTC) might function as early markers for breast cancer metastasis or monitoring therapy efficacy. Enrichment and identification of CTCs are based on epithelial markers that might be modulated during epithelial-mesenchymal transition. Little is known about the expression of keratins in CTCs and whether all CTCs can be detected with antibodies directed against a limited panel of keratins.Experimental Design: Protein expression of keratin 2, 4-10, 13-16, 18, and 19 were assessed by a cocktail of antibodies (C11, AE1, AE3, and K7) and keratin antibodies C11 and A45-B/B3 alone in 11 breast cancer cell lines and 50 primary breast carcinomas and their lymph node metastases. Furthermore, CTCs were assessed in blood of 70 metastatic breast cancer patients.Results: Claudin-low cell lines did not show expression of normal breast epithelial keratins but were positive for K14 and K16, detected by the cocktail only. Primary breast carcinomas showed changes in keratin expression during metastatic progression to the lymph nodes. In 35 of 70 patients CTCs were identified, of which 83%, 40%, and 57% were identified by the cocktail, C11 and A45-B/B3, respectively. Identification of CTCs by the cocktail was associated with shorter survival (P < 0.01). In silico analyses revealed association between KRT16 expression and shorter relapse-free survival in metastatic breast cancer.Conclusion: Breast cancer cells show a complex pattern of keratin expression with potential biologic relevance. Individual keratin antibodies recognizing only a limited set of keratins inherit the risk to miss biologically relevant CTCs in cancer patients, and antibody cocktails including these keratins are therefore recommended.

show abstract

“…CTCs have been shown to be a powerful prognostic biomarker in many types of cancer, including breast cancer. [12] In our investigations of CTCs, we faced two challenges: Identifying these rare cells and confirming their metastatic potential. Large differences in the detection rates of CTCs (30-100%) have been reported in breast cancer.…”

Section: Discussionmentioning

confidence: 99%

The prognostic value of circulating tumor cells lacking cytokeratins in metastatic breast cancer patients

Zhao

et al. 2013

J Can Res Ther

View full text Add to dashboard Cite

show abstract

Circulating Tumor Cells in the Management of Breast Cancer

Cited by 17 publications

References 41 publications

BMP-6 inhibits MMP-9 expression by regulating heme oxygenase-1 in MCF-7 breast cancer cells

BMP-6 inhibits MMP-9 expression by regulating heme oxygenase-1 in MCF-7 breast cancer cells

Changes in Keratin Expression during Metastatic Progression of Breast Cancer: Impact on the Detection of Circulating Tumor Cells

The prognostic value of circulating tumor cells lacking cytokeratins in metastatic breast cancer patients

Contact Info

Product

Resources

About